Evidence map›Paper›PMID 42051526›Full record

ReviewFrontiers in immunology2026

Pathological mechanisms and research progress of multilevel intervention therapy for coronary heart disease.

Zhengyu Tu, Yuxin Wei, Yuanpeng Liao, Zhengdong Wan, Zhongquan Zhou, Jiawei Guo

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhengyu Tu *Department of Cardiology, The First Affiliated Hospital of Yangtze University, Jingzhou, China.
Yuxin Wei *Department of Cardiology, The First Affiliated Hospital of Yangtze University, Jingzhou, China.
Yuanpeng Liao *Department of Cardiology, The First Affiliated Hospital of Yangtze University, Jingzhou, China.
Zhengdong WanDepartment of Vascular and Endovascular Surgery, The First Affiliated Hospital of Yangtze University, Jingzhou, China.
Zhongquan ZhouDepartment of Pharmacology, School of Medicine, Yangtze University, Jingzhou, China.
Jiawei GuoDepartment of Cardiology, The First Affiliated Hospital of Yangtze University, Jingzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronary heart disease (CHD) is a chronic cardiovascular disease with coronary atherosclerosis as the main pathological basis. Its occurrence and progression are not a simple process of lipid deposition, but a systemic pathological process jointly driven by metabolic disorders, chronic low-grade inflammation, and immune imbalance. Recent studies have shown that endothelial dysfunction is a key event in the early occurrence of CHD. Abnormal lipid metabolism, immune cell infiltration, and continuous activation of inflammatory signals together promote plaque formation, maturation, and destabilization. Especially under the regulation of the metabolism-inflammation-immunity network, a positive feedback loop is formed between immune cell metabolic reprogramming, macrophage polarization, inflammasome activation, and oxidative stress response, which accelerates the progression of atherosclerosis and increases the risk of acute coronary events. Traditional therapeutic strategies centered on lipid-lowering, antiplatelet therapy, and revascularization can reduce the incidence of short-term events, but there are still limitations in long-term risk control and fundamental reversal of the disease. From a narrative perspective, this article summarizes the research progress of CHD in pathological mechanisms, metabolism and immune regulation, plaque instability, and risk factors from a systematic perspective and focuses on discussing the potential value of multilevel and systematic intervention strategies in the precise prevention and treatment of CHD, providing a theoretical basis for future translational research and personalized treatment.

Indexed as

Coronary DiseaseAnimalsCoronary Artery DiseaseHumansLipid MetabolismPlaque, AtheroscleroticRisk Factorsatherosclerosiscoronary heart diseaseendothelial dysfunctionmetabolism-inflammation-immunity networkmulti-level intervention therapyvulnerable plaque

Identifiers

PMID42051526
PMCPMC13110956

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.